Altered bone remodeling in psoriatic arthritis

Current Rheumatology Reports

Volumn 10, Issue 4, 2008, Pages 311-317

  Mensah, Kofi A ^a   Schwarz, Edward M ^a   Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALKALINE PHOSPHATASE; BONE MORPHOGENETIC PROTEIN; DICKKOPF 1 PROTEIN; ETANERCEPT; FRIZZLED PROTEIN; INFLIXIMAB; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MEMBRANE PROTEIN; MESSENGER RNA; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SMAD PROTEIN; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR; DKK1 PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

BONE REMODELING; CELL DIFFERENTIATION; CELL DISRUPTION; CLINICAL FEATURE; CLINICAL TRIAL; DACTYLITIS; DENDRITIC CELL; ENTHESITIS; ENZYME INHIBITION; FINGER MALFORMATION; GENE ACTIVATION; GENE OVEREXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PHAGOCYTE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PSORIATIC ARTHRITIS; REVIEW; SIGNAL TRANSDUCTION; SPONDYLOARTHROPATHY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; UPREGULATION; BONE DEVELOPMENT; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ARTHRITIS, PSORIATIC; BONE RESORPTION; HUMANS; IMMUNOLOGIC FACTORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53249119837     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-008-0050-5     Document Type: Review

References (45)

1. TeitelbWum SL: Osteoclasts: what do they do and how do they do it? Am J Pathol 2007, 170: 427-435.
2. Rho J, TakaIi M, Choi Y: Osteoimmunology: interactions of the immune and skeletal systems. Mol Cells 2004, 17: 1-9.
3. Rodan GA, Martin TJ: Therapeutic approaches to bone disease. Science 2000, 289: 1508-1514.
4. Takayanagi H, Ogasawara K, Hida S, et al.: T-cell-mediated regulation of osteoclastogenesis by signaling crosstalk between RANKL and IFN-gamma. Nature 2000, 408: 600-605.
5. Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 2003, 423: 337-342.
6. Lories RJ, Derese I, Luyten FP: Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005, 115: 1571-1579.
7. Walsh MC, KIm N, Kadono Y, et al.: Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006, 24: 33-63.
8. Takayanagi S: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007, 7: 292-304.
9. Baron R, Rawadi G: Minireview: Targeting the Wnt/B-Catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007, 148: 2635-2643.
10. Yamaguchi A, Komori T, Suda T: Reulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs and Cbfa1. Endocrine Reviews 2000, 21: 393-411.
11. Diarra D, Stolina M, Polzer K, et al.: Dickkopf-1 is a master regulator of joint remodeling. Nat Medicine 2007, 13: 156-163.
12. Miyamoto T, Ohneda O, Arai F, et al.: Bifurcation of osteoclasts and dendritic cells from common progenitors. Blood 2001, 98: 2544-2554.
13. Arai F, Miyamoto T, Ohneda O, et al.: Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor {kappa}B (RANK) receptors. J Exp Med 1999, 190: 1741-1754.
14. Vignery A: MaTrophage fusion: the making of osteoclasts and giant cells. J Exp Med 2005, 202: 337-340.
15. Kukita T, Wada N, Kukita A, et al.: RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 2004, 200: 941-946.
16. Yagi M, Miyamoto T, Sawatani Y, et al.: DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005, 202: 345-351.
17. Roodman GD: Advances in bone biology, the osteoclast. Endocr Rev 1996, 17: 308-332.
18. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000, 289: 1504-1508.
19. Wong BR, Rho J, Arron J, et al.: TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T-cells. J Biol Chem 1997, 272: 25190-25194.
20. Anderson DM, Maraskovsky E, Billingsley WL, et al.: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997, 390: 175-179.
21. Kong YY, Feige U, Sarosi I, et al.: Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402: 304-309.
22. Kim N, Odgren PR, Kim DK, et al.: Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 2000, 97: 10905-10910.
23. Fitzgerald O: Advances in understanding and novel therapeutic targets in inflammatory arthritis. Ir J Med Sci 1995, 164: 4-11.
24. Ritchlin C, Haas-Smith SA, Hicks D, et al.: Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998, 25: 1544-1552.
25. Partsch G, Steiner G, Leeb BF, et al.: Highly increased levels of tumor necrosis factor-a and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997, 24: 518-523.
26. McInnes IB, Illei GG, Danning CL: IL-10 Improves skin disease and modulates endothelial activation and leukocyte effector function in patients with psoriatic arthritis. J Immunol 2001, 167: 4075-4082.
27. Gladman DD, Farewell VT, Nadeau C, et al.: Clinical indicators of progression in psoriatic arthritis: Multivariate relative risk model. J Rheumatol 1995, 22: 675-679.
28. Suda T, Takahashi N, Udagawa N, et al.: Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999, 20: 345-357.
29. Li P, Schwarz EM: The TNF-alpha transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003, 25: 19-33.
30. Abu-Amer Y, Erdmann J, Kollias G, et al.: Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 2000, 275: 27307-27310.
31. Keffer J, Probert L, Cazlaris H, et al.: Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J 1991, 10: 4025-4031.
32. Li P, Schwarz EM, O'Keefe RJ, et al.: Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. Arthritis Rheum 2004, 50: 265-276.
33. Zenz R, Eferl R, Kenner L, et al.: Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. 2005, 437: 369-375.
34. Simonet WS,ALacey DL, Dunstan CR, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309-319.
35. Mease PJ: Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis 2002, 61: 298-304.
36. Rahman P, Siannis F, Butt C, et al.: TNFa polymorphisms and risk of psoriatic arthritis. Ann Rheum Dis 2006, 65: 919-923.
37. Ritchlin CT, Haas-Smith S, Li P, et al.: Mechanisms of TNF-a-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003, 111: 821-831.
38. Anandarajah AP, Schwarz EM, Totterman S, et al.: The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008, 67: 296-301.
39. Kaneki H, Guo R, Chen D, et al.: Tumor necrosis factor promotes runx2 degradation through up-regulation of smurf1 and smurf2 in osteoblasts. J Biol Chem 2006, 281: 4326-4333.
40. Mease PJ: Psoriatic arthritis update. Bull NYU Hosp Jt Dis 2006, 64: 25-31.
41. van der Heijde D, Kavanaugh A, Gladman DD, et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007, 56: 2698-2707.
42. Mease PJ, Gladman DD, Ritchlin CT, et al.; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52: 3279-3289.
43. Van der Heijde DM, Landewe RD, Ory P, et al.: Etanercept does not inhibit radiographic progression in patients with ankylosing spondylitis [abstract]. Ann Rheum Dis 2006, 65(SII): 81.
44. Lories RJ, Derese I, Bari C, et al.: Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007, 56: 489-497.
45. Taylor W, Gladman D, Helliwell P, et al.: Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum 2006, 54: 2665-2673.